Strong Q3 sales at Cambrex

Cambrex reported that sales in Q3 2011 rose 18% to $58.2m including a 7% rise due to favourable exchange rates. The company said that higher volumes of an API for a customer who experienced a disruption in its supply chain for most of 2010, higher volumes of controlled substances, products utilising its drug delivery technology and a recently approved innovator product were the main reasons for the rise. These were partially offset by lower pricing across several product categories, lower sales of generic APIs and lower custom development shipments.
Cambrex